ESR1 and breast cancer: Two, quite recent, large case-control studies have highlighted the clinical implications associated with missense CHEK2 variants, since they were found to be associated with moderate breast cancer risk, while a strong association of all CHEK2 pathogenic variants with estrogen receptor positive breast cancer was revealed [4,5].